ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets

Stem Cells

Volumn 30, Issue 10, 2012, Pages 2100-2113

  Luo, Yuchun ^a   Dallaglio, Katiuscia ^a,b   Chen, Ying ^b   Robinson, William A ^a   Robinson, Steven E ^a   McCarter, Martin D ^b   Wang, Jianbin ^a   Gonzalez, Rene ^a   Thompson, David C ^b   Norris, David A ^a,c   Roop, Dennis R ^a,b   Vasiliou, Vasilis ^b   Fujita, Mayumi ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldehyde dehydrogenase; Cancer stem cells; Melanoma; Microarray analysis; Molecular targeted therapy; Tumor initiating cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A; ALDEHYDE DEHYDROGENASE 1A3; MESSENGER RNA; PROTEIN CDC42; RETINOIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL RENEWAL; CELL VIABILITY; ENZYME ACTIVITY; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PROTEIN EXPRESSION; SCID MOUSE; STEM CELL; XENOTRANSPLANTATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; ISOENZYMES; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRETINOIN;

MUS;

EID: 84866671365     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1193     Document Type: Article

References (53)

1. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
2. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65:9328-9337.
3. Monzani E, Facchetti F, Galmozzi E et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-946.
4. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 2008;451:345-349.
5. Boiko AD, Razorenova OV, van de Rijn M et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-137.
6. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
7. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-598.
8. Quintana E, Shackleton M, Foster HR et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-523.
9. Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: The 2002 update. Chem Biol Interact 2003;143-144:5-22.
10. Magni M, Shammah S, Schiro R et al. Induction of cyclophosphamide- resistance by aldehyde-dehydrogenase gene transfer. Blood 1996;87:1097-1103.
11. Armstrong L, Stojkovic M, Dimmick I et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004;22:1142-1151.
12. Hess DA, Meyerrose TE, Wirthlin L et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104: 1648-1655.
13. Hess DA, Wirthlin L, Craft TP et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006;107:2162-2169.
14. Corti S, Locatelli F, Papadimitriou D et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006;24:975-985.
15. Levi BP, Yilmaz OH, Duester G et al. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood 2009;113:1670-1680.
16. Burger PE, Gupta R, Xiong X et al. High aldehyde dehydrogenase activity: A novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27:2220-2228.
17. Todaro M, Iovino F, Eterno V et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010;70: 8874-8885.
18. Ucar D, Cogle CR, Zucali JR et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009;178: 48-55.
19. Jiang F, Qiu Q, Khanna A et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009;7:330-338.
20. van den Hoogen C, van der Horst G, Cheung H et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70:5163-5173.
21. Rasheed ZA, Yang J, Wang Q et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-351.
22. Wang L, Park P, Zhang H et al. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 2011;128:294-303.
23. Clay MR, Tabor M, Owen JH et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010;32:1195-1201.
24. Croker AK, Goodale D, Chu J et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009;13:2236-2252.
25. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
26. Carpentino JE, Hynes MJ, Appelman HD et al. Aldehyde dehydrogenase- expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 2009;69:8208-8215.
27. Chen YC, Chen YW, Hsu HS et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009;385:307-313.
28. Charafe-Jauffret E, Ginestier C, Iovino F et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010;16:45-55.
29. Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
30. Silva IA, Bai S, McLean K et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
31. Prasmickaite L, Engesaeter BO, Skrbo N et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One 2010;5:e10731.
32. Boonyaratanakornkit JB, Yue L, Strachan LR et al. Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol 2010;130:2799-2808.
33. Luo Y, Ellis LZ, Dallaglio K et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol 2012 [Epub ahead of print].
34. Rubio-Viqueira B, Jimeno A, Cusatis G et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661.
35. Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2005;2:138-143.
36. Marchitti SA, Brocker C, Stagos D et al. Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 2008;4:697-720.
37. Eyler CE, Rich JN. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-2845.
38. Bleehen NM, Newlands ES, Lee SM et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-913.
39. Bedikian AY, Plager C, Papadopoulos N et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004;14:63-66.
40. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823-2830.
41. Vorobiof DA, Rapoport BL, Mahomed R et al. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 2003;13:201-203.
42. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci 1992;17:427-433.
43. Balmer JE, Blomhoff R. A robust characterization of retinoic acid response elements based on a comparison of sites in three species. J Steroid Biochem Mol Biol 2005;96:347-354.
44. Frank NY, Schatton T, Kim S et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71:1474-1485.
45. Ishizawa K, Rasheed ZA, Karisch R et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010;7:279-282.
46. Girouard SD, Murphy GF. Melanoma stem cells: Not rare, but well done. Lab Invest 2011;91:647-664.
47. Civenni G, Walter A, Kobert N et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-3109.
48. Ghadially R. The role of stem and circulating cells in cancer metastasis. J Surg Oncol 2011;103:555-557.
49. Chute JP, Muramoto GG, Whitesides J et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;103:11707-11712.
50. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-1313.
51. Marcato P, Dean CA, Pan D et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011;29:32-45.
52. Pares X, Farres J, Kedishvili N et al. Medium- and short-chain dehydrogenase/ reductase gene and protein families: Medium-chain and short-chain dehydrogenases/reductases in retinoid metabolism. Cell Mol Life Sci 2008;65:3936-3949.
53. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-1261.